Cheetah Medical's NICOM(R) System for Noninvasive Hemodynamic Monitoring Found to be an Effective Tool for Identification of Acute Heart Failure in the Emergency Department

Cleveland Clinic Researchers Find That NICOM(R) Technology Provides a Quick Noninvasive Tool to Help Diagnose Acute Heart Failure in Patients Presenting to the Emergency Department With Shortness of Breath

TEL AVIV, Israel, November 4, 2010 - A study performed by investigators from the Emergency
Department of the Cleveland Clinic Foundation finds that Cheetah Medical's
NICOM system is effective in identification of acute heart failure (AHF) and
in differentiating it from other acute situations with similar clinical
presentations. The study was published last week in the American Journal of
Emergency Medicine.

Heart failure exacerbation is a potentially life-threatening
condition which frequently manifests as shortness of breath, or "dyspnea." In
2006, over 3 million visits to hospital emergency departments were for a
chief complaint of shortness of breath. In addition to heart failure,
shortness of breath is associated with a variety of other diagnoses involving
the lungs, heart and other organs, including chronic obstructive pulmonary
disease (COPD), asthma, metabolic and psychiatric conditions. Early, correct
diagnosis and management is key to improve outcomes while relieving heavy
patient burdens in hospital emergency departments.

In this study, the Cheetah Medical NICOM(R) Noninvasive
Cardiac Output & Hemodynamic Monitoring System was able to distinguish heart
failure patients from patients diagnosed with COPD, asthma and dyspnea for
other reasons. This US FDA-cleared, fully non-invasive bedside test utilizes
a set of four sensors applied on the patient's chest or back. In this study,
the system was used to monitor patients' hemodynamics around a change in
patient position, also known as "orthostatic challenge". The NICOM system
captured the markedly different hemodynamic response of heart failure patents
as compared to the other causes of dyspnea and to accurately differentiate
between heart failure and other conditions.

Rakesh Engineer, MD, FACEP, Discipline Leader, Emergency &
Undifferentiated Care at the Cleveland Clinic Lerner College of Medicine and
the study's Primary Investigator, said: "Acute heart failure affects 5.8
million Americans per year, with costs exceeding $33 billion. Clinical
judgment, even when combined with our best biomarkers, produces a diagnostic
accuracy of only 82.5%. Clearly, new methods to determine the etiology of
shortness of breath in emergency patients are needed. This study illustrates
the utility of NICOM Bioreactance Technology in differentiating acute heart
failure from asthma and COPD".

W. Frank Peacock, MD, FACEP, Vice Chair, Emergency Medicine
Institute, Cleveland Clinic Foundation, and the study's Senior Author, said:
"Outcomes in patients presenting to the emergency department with acute
shortness of breath are related to appropriate and timely therapy. When
therapy is delayed or inappropriate, the acute mortality rate is increased.
Our data suggest that an early and accurate heart failure diagnosis can be
determined by measuring hemodynamic changes using NICOM Technology."

About Acute Heart Failure and Its Diagnosis in the Emergency
Department

Emergency department (ED) visits for symptoms related to heart
failure are very common, responsible for about 5% of annual visits to the ED
in the US. Determining the most accurate early diagnosis of heart failure
remains a clinical challenge. The best currently available diagnostic
laboratory tests and clinical decision-making in the emergency department
yield a diagnostic accuracy for acute heart failure of about 80%. Acute heart
failure requires rapid diagnosis and management as it is associated with
significant near-term mortality and high healthcare costs. There are over one
million annual hospital admissions for heart failure in the U.S. alone, with
total national hospital costs exceeding $33 billion. Initiating the earliest
appropriate treatment protocols for acute heart failure can help to reduce
patient morbidity and mortality, as well as reduce healthcare costs.

About Cheetah Medical

Cheetah Medical's NICOM(R) Noninvasive Cardiac Output and Hemodynamic
Monitoring System uses the company's proprietary BIOREACTANCE(R) Technology
to deliver continuous, accurate, noninvasive cardiac output (CO) and other
vital hemodynamic monitoring parameters, useful for fluid management and drug
titration. The system is US FDA cleared and CE Marked, and since its
commercial launch in 2008 has been adopted by a growing number of clinicians
worldwide. Cheetah Medical headquarters is located in Tel-Aviv, Israel and
its United States headquarters is located in Portland, Oregon. For more
information, visit our website at www.cheetah-medical.com.

    For More Information Contact:

    Yoav Avidor, MD
    Chief Executive Officer
    Cheetah Medical
    yoav@cheetah-medical.com
    Telephone: +972-3-644-0288

For More Information Contact: Yoav Avidor, MD, Chief Executive Officer, Cheetah Medical, yoav at cheetah-medical.com, Telephone: +972-3-644-0288